Ken Griffin Recursion Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$5.92 - $8.6 $253,968 - $368,940	42,900 Added 16.73%	299,300 $1.97 Million
Q2 2024 Aug 14, 2024	BUY	$7.35 - $10.05 $258,720 - $353,760	35,200 Added 15.91%	256,400 $1.92 Million
Q1 2024 May 15, 2024	BUY	$9.13 - $15.52 $849,090 - $1.44 Million	93,000 Added 72.54%	221,200 $2.21 Million
Q4 2023 Feb 14, 2024	BUY	$5.09 - $10.79 $251,955 - $534,105	49,500 Added 62.9%	128,200 $1.26 Million
Q3 2023 Nov 14, 2023	BUY	$6.59 - $15.86 $353,224 - $850,096	53,600 Added 213.55%	78,700 $602,000
Q2 2023 Aug 14, 2023	BUY	$4.56 - $9.94 $13,223 - $28,826	2,900 Added 13.06%	25,100 $187,000
Q1 2023 May 15, 2023	BUY	$6.42 - $9.64 $19,902 - $29,884	3,100 Added 16.23%	22,200 $148,000
Q4 2022 Feb 14, 2023	BUY	$7.16 - $12.7 $716 - $1,270	100 Added 0.53%	19,100 $147,000
Q3 2022 Nov 14, 2022	SELL	$7.83 - $13.6 $76,734 - $133,280	-9,800 Reduced 34.03%	19,000 $202,000

286

242M

1.35M

2.32M

Ticker RXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 180,480,000
Market Cap $1.33B
Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.